Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer

Journal of Controlled Release

Volumn 110, Issue 2, 2006, Pages 323-331

  Gao, Song Qi ^a   Lu, Zheng Rong ^a   Petri, Boris ^a   Kopečková, Pavla ^a,b   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

1,6 elimination; Aromatic azo bond cleavage; Colon specific drug delivery; Drug release; HPMA copolymer 9 aminocamptothecin conjugate

Indexed keywords

AZO DYES; DEGRADATION; DRUG THERAPY; SYNTHESIS (CHEMICAL); TUMORS;

1,6-ELIMINATION; AROMATIC AZO BOND CLEVAGE; COLON-SPECIFIC DRUG DELIVERY; DRUG RELEASE; HPMA COPOLYMER-9-AMINOCAMPTOTHECIN CONJUGATE;

COPOLYMERS;

9 AMINOCAMPTOTHECIN; CARBAMIC ACID DERIVATIVE; COPOLYMER; DRUG CARRIER; N (2 HYDROXYPROPYL)METHACRYLAMIDE;

ANIMAL TISSUE; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG ELIMINATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; INTESTINE MUCOSA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE;

ANIMALS; BUFFERS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; DRUG DELIVERY SYSTEMS; INDICATORS AND REAGENTS; INTESTINAL MUCOSA; INTESTINE, LARGE; INTESTINE, SMALL; MALE; METHACRYLATES; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, FLUORESCENCE;

EID: 29244439607     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.10.004     Document Type: Article

References (41)

1. B.C. Giovanella, J.S. Stehlin, M.E. Wall, M.C. Wani, A.W. Nicholas, L.F. Liu, R. Silber, and M. Potmesil DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts Science 246 1989 1046 1048
2. M. Potmesil, S.G. Arbuck, C.H. Takimoto, L. Liebes, and H. Hochster 9-Aminocamptothecin and beyond, preclinical and clinical studies Ann. N.Y. Acad. Sci. 803 1996 231 246
3. J.J. Champoux Mechanism of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to 3′-terminus of the nicked DNA J. Mol. Biol. 118 1978 441 446
4. M. Gupta, A. Fujimori, and Y. Pommier Eukaryotic DNA topoisomerases I Biochim. Biophys. Acta 1262 1995 1 14
5. J.T. Stivers, T.K. Harris, and A.S. Mildvan Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation Biochemistry 36 1997 5212 5222
6. Y.H. Hsiang, and L.F. Liu Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin Cancer Res. 48 1988 1722 1726
7. Y.P. Tsao, A. Russo, G. Nyamuswa, R. Silber, and L.F. Liu Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system Cancer Res. 53 1993 5908 5914
8. A. Nakashio, N. Fujita, S. Rokudai, S. Sato, and T. Tsuruo Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis Cancer Res. 60 2000 5303 5309
9. R. Yao, and G.M. Cooper Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor Science 267 1995 2003 2006
10. C.H. Takimoto Why drugs fail: of mice and men revisited Clin. Cancer Res. 7 2001 229 230
11. H.L. McLeod, F. Douglas, M. Oates, R.P. Symonds, D. Prakash, A.G. van der Zee, S.B. Kaye, R. Brown, and W.N. Keith Topoisomerase I and II activity in human breast, cervix, lung and colon cancer Int. J. Cancer 59 1994 607 611
12. C.J. Gerrits, M.J. de Jonge, J.H. Schellens, G. Stoter, and J. Verweij Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development Br. J. Cancer 76 1997 952 962
13. E. Rubin, V. Wood, A. Bharti, D. Trites, C. Lynch, S. Hurwitz, S. Bartel, S. Levy, A. Rosowsky, and D. Toppmeyer A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin Clin. Cancer Res. 1 1995 269 276
14. W. Dahut, N. Harold, C. Takimoto, C. Allegra, A. Chen, J.M. Hamilton, S. Arbuck, M. Sorensen, F. Grollman, H. Nakashima, R. Lieberman, M. Liang, W. Corse, and J. Grem Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients J. Clin. Oncol. 14 1996 1236 1244
15. M.N. Kirstein, P.J. Houghton, P.J. Cheshire, L.B. Richmond, A.K. Smith, S.K. Hanna, and C.F. Stewart Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts Clin. Cancer Res. 7 2001 358 366
16. J. Kopeček, P. Kopečková, T. Minko, and Z. Lu HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action Eur. J. Pharm. Biopharm. 50 2000 61 81
17. Y. Grim, and J. Kopeček Bioadhesive water-soluble polymeric drug carriers for site-specific oral drug delivery. Synthesis, characterization, and release of 5-aminosalicylic acid by Streptococcus faecium in vitro New Polym. Mater. 3 1991 49 59
18. P. Kopečková, R. Rathi, S. Takada, B. Ří hová, M.M. Berenson, and J. Kopeček Bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers for colon-specific drug delivery J. Control. Release 28 1994 211 222
19. S. Sakuma, Z.R. Lu, P. Kopečková, and J. Kopeček Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin J. Control. Release 75 2001 365 379
20. S. Sakuma, Z.-R. Lu, B. Pecharová, P. Kopečková, and J. Kopeček N-(2-Hydroxypropyl)methacrylamide copolymer-9- aminocamptothecin conjugate: colon-specific delivery in rats J. Bioact. Compat. Polym. 17 2002 305 319
21. P. Kopečková, K. Ikesue, and J. Kopeček Cleavage of oligopeptide p-nitroanilides attached to N-(2-hydroxypropyl)methacrylamide copolymers by guinea pig intestinal enzymes Makromol. Chem. 193 1992 2605 2619
22. P.L. Carl, P.K. Chakravarty, and J.A. Katzenellenbogen A novel connector linkage applicable in prodrug design J. Med. Chem. 24 1981 479 480
23. B.E. Toki, C.G. Cerveny, A.F. Wahl, and P.D. Senter Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs J. Org. Chem. 67 2002 1866 1872
24. F.M. de Groot, W.J. Loos, R. Koekkoek, L.W. van Berkom, G.F. Busscher, A.E. Seelen, C. Albrecht, P. de Bruijn, and H.W. Scheeren Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release J. Org. Chem. 66 2001 8815 8830
25. J. Kopeček, and H. Bažilová Poly[N-(2-hydroxypropyl) methacrylamide]: 1. Radical polymerization and copolymerization Eur. Polym. J. 9 1973 7 14
26. C.H. Takimoto, R.W. Klecker, W.L. Dahut, L.K. Yee, J.M. Strong, C.J. Allegra, and J.L. Grem Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography J. Chromatogr., B, Biomed. Appl. 655 1994 97 104
27. A. Hatefi, and B. Amsden Camptothecin delivery methods Pharm. Res. 19 2002 1389 1399
28. C.D. Conover, and R.B. Greenwald Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker Cancer Chemother. Pharmacol. 42 1998 407 414
29. M. Harada, J.-I. Murata, Y. Sakamura, H. Sakakibara, S. Okuno, and T. Suzuki Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor and tumor-bearing rats J. Control. Release 71 2001 71 86
30. J.W. Singer, R. Bhatt, J. Tulinsky, K.R. Buhler, E. Heasley, P. Klein, and P. de Vreis Water-soluble poly(l-glutamic acid)-Gly-camtothecin conjugates enhance camptothecin stability and efficacy in vivo J. Control. Release 74 2001 243 247
31. M. Zamai, M. VandeVen, M. Farao, E. Gratton, A. Ghiglieri, M.G. Castelli, E. Fontana, R. D'Argy, A. Fiorino, E. Pesenti, A. Suarato, and V.R. Caiolfa Camptothecin poly[N-(2-hydroxypropyl)methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy Mol. Cancer Ther. 2 2003 29 40
32. S. Balasubramanian, J. Kim, D.Y. Kim, J. Kumar, and S.K. Tripathy Water-soluble, conjugated main chain azo polymer: synthesis and characterization Macromol. Rapid Commun. 17 1996 853 857
33. P.Y. Yeh, P. Kopečková, and J. Kopeček Biodegradable and pH-sensitive hydrogels: synthesis by cross-linking of N,N-dimethacrylamide copolymer precursors J. Polym. Sci. 32 1994 1627 1637
34. M. Saffran, G.S. Kumar, C. Savariar, J.C. Burnham, F. Williams, and D.C. Neckers A new approach to the oral administration of insulin and other peptide drugs Science 233 1986 1081 1084
35. G. Van den Mooter, C. Samyn, and R. Kinget Azo polymers for colon-specific drug delivery: II. Influence of the type of azo polymer on the degradation by intestinal microflora Int. J. Pharm. 97 1993 133 139
36. J.P. Brown, G.V. McGarraugh, T.M. Parkinson, J.R.E. Wingard, and A.B. Oderdonk A polymeric drug for treatment of inflammatory bowel disease J. Med. Chem. 26 1983 1300 1307
37. H. Brøndsted, and J. Kopeček Hydrogels for site-specific drug delivery to colon: in vitro and in vivo degradation Pharm. Res. 9 1992 1540 1545
38. Č. Koňák, P. Kopečková, and J. Kopeček Photoregulated association of N-(2-hydroxypropyl)methacrylamide copolymers with azobenzene containing side-chains Macromolecules 25 1992 5451 5456
39. G. Chirico, M. Collini, F. Olivini, M. Zamai, E. Frigeiro, and V.R. Caiolfa Aggregation properties of a HPMA-camptothecin copolymer in isotonic solutions Biophys. Chem. 110 2004 281 295
40. Z.R. Lu, S.Q. Gao, P. Kopečková, and J. Kopeček Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates Bioconjug. Chem. 11 2000 3 7
41. S. Wróblewski, M. Berenson, P. Kopečková, and J. Kopeček Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues J. Biomed. Mater. Res. 51 2000 329 342